NASDAQ:PXMD - Nasdaq - US70424C2035 - Common Stock - Currency: USD
0.6883
-0.06 (-7.61%)
The current stock price of PXMD is 0.6883 USD. In the past month the price increased by 27.7%. In the past year, price decreased by -97.28%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.62 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York and currently employs 3 full-time employees. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
PAXMEDICA INC
303 South Broadway, Suite 125
Tarrytown NEW YORK US
Employees: 3
Company Website: https://www.paxmedica.com/
Phone: 19149872876
The current stock price of PXMD is 0.6883 USD. The price decreased by -7.61% in the last trading session.
The exchange symbol of PAXMEDICA INC is PXMD and it is listed on the Nasdaq exchange.
PXMD stock is listed on the Nasdaq exchange.
null analysts have analysed PXMD and the average price target is 3.06 USD. This implies a price increase of 344.57% is expected in the next year compared to the current price of 0.6883. Check the PAXMEDICA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PAXMEDICA INC (PXMD) has a market capitalization of 5.10M USD. This makes PXMD a Nano Cap stock.
PAXMEDICA INC (PXMD) currently has 3 employees.
PAXMEDICA INC (PXMD) has a support level at 0.68 and a resistance level at 0.75. Check the full technical report for a detailed analysis of PXMD support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PXMD does not pay a dividend.
PAXMEDICA INC (PXMD) will report earnings on 2024-05-13.
PAXMEDICA INC (PXMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.85).
The outstanding short interest for PAXMEDICA INC (PXMD) is 0.01% of its float. Check the ownership tab for more information on the PXMD short interest.
ChartMill assigns a technical rating of 3 / 10 to PXMD. When comparing the yearly performance of all stocks, PXMD is a bad performer in the overall market: 88.21% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to PXMD. The financial health of PXMD is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months PXMD reported a non-GAAP Earnings per Share(EPS) of -15.85. The EPS increased by 23.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -321.98% | ||
ROE | -540.3% | ||
Debt/Equity | 0 |